Glucagon-like peptide-1 (GLP-1) receptor agonists are the newest class of T2D therapy currently available, which improve hyperglycemia through increasing insulin secretion and reducing glucagon secretion [7,8], slowing gastric emptying, delaying carbohydrate absorption, and increasing satiety, leading to reduced caloric intake [9]. Here, GCG is linked to type 2 diabetes mellitus.